| abstract |
The present disclosure relates, in part, to dosing regimens of α-synuclein antibodies or α-synuclein binding fragments thereof, and their use in the treatment of synucleinopathies. These dosing regimens include synucleinopathies such as Parkinson's disease (PD), Parkinson's disease dementia (PDD), Lewy body dementia (DLB), Lewy body variants of Alzheimer's disease (LBVAD), pure autonomy. It finds use in the treatment of neurological deficiency (PAF), multiple system atrophy (MSA), and type 1 intracerebral iron deposition neurodegeneration (NBIA-I). [Selection diagram] Fig. 5 |